The present invention provides an agent that increases the expression of BAD,for use in the treatment of cancer in conjunction with a chemotherapeuticagent wherein theagent is selected from the list consisting of 6-.beta.-naltrexol, naloxone,methylnaltrexone, orpharmaceutically acceptable salts thereof.